Cargando…

Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas

BACKGROUND: This study aimed to explore the efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinomas (LA-HNSCCs). METHODS: In this prospective, single-arm, single-centre clinical trial,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Kai, Gui, Lin, Lu, Haizhen, He, Xiaohui, Li, Dezhi, Liu, Chang, Liu, Shaoyan, Wang, Xiaolei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425220/ https://www.ncbi.nlm.nih.gov/pubmed/37583698 http://dx.doi.org/10.3389/fimmu.2023.1189752

Ejemplares similares

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
por: Shen, Dijian, et al.
Publicado: (2021)

Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma
por: Yi, Junlin, et al.
Publicado: (2017)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
por: Duan, Hongtao, et al.
Publicado: (2022)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Feng, Zhien, et al.
Publicado: (2011)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study
por: Wang, Kai, et al.
Publicado: (2019)

Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis
por: Ma, Jie, et al.
Publicado: (2013)

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
por: Luginbuhl, Adam J., et al.
Publicado: (2022)

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma
por: Spathas, Nikolaos, et al.
Publicado: (2018)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
por: Larkins, Erin, et al.
Publicado: (2017)

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
por: Harrington, Kevin J., et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

The oncological outcome and influence of neoadjuvant chemotherapy on the surgery in the resectable and locally advanced oral squamous cell carcinoma
por: Su, Xuan, et al.
Publicado: (2019)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy
por: Haque, Sulsal, et al.
Publicado: (2017)

A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma
por: Nindra, Udit, et al.
Publicado: (2023)

Biomarkers predictive of response to pembrolizumab in head and neck cancer
por: Pfister, David G., et al.
Publicado: (2022)

A Preoperative Nomogram for Predicting Chemoresistance to Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Squamous Carcinoma Treated with Radical Hysterectomy
por: Ou, Zhengjie, et al.
Publicado: (2021)

Case of needle tract seeding during preoperative neoadjuvant chemotherapy for resectable pancreatic cancer
por: Yane, Kei, et al.
Publicado: (2022)

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022)

Concurrent radiotherapy and chemotherapy for locally advanced squamous cell carcinoma of the head and neck
por: Ali, Elsayed M, et al.
Publicado: (2011)

Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma
por: Wang, Liping, et al.
Publicado: (2022)

Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
por: Patil, Vijay M., et al.
Publicado: (2016)

Neoadjuvant chemotherapy in technically unresectable head and neck cancers: a retrospective audit
por: Mishra, Bal Krishna, et al.
Publicado: (2022)

Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study
por: Zhao, Guangyin, et al.
Publicado: (2023)

Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012
por: Tahara, Makoto, et al.
Publicado: (2018)

Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer
por: Zhang, Lin, et al.
Publicado: (2020)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

New developments in the management of head and neck cancer – impact of pembrolizumab
por: Saleh, Khalil, et al.
Publicado: (2018)

Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
por: Bulbul, Ajaz
Publicado: (2019)

Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States
por: Liu, Maobai, et al.
Publicado: (2019)

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
por: Ferris, Robert L, et al.
Publicado: (2021)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023)

Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery
por: Tsuboi, Tomofumi, et al.
Publicado: (2016)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

Preoperative anemia and perioperative blood transfusion in head and neck squamous cell carcinoma
por: Baumeister, Philipp, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k79feeq6ros4lkr8f55nudagud